X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (59) 59
humans (46) 46
melanoma (45) 45
oncology (44) 44
female (30) 30
male (30) 30
cancer (27) 27
middle aged (26) 26
immunotherapy (23) 23
aged (22) 22
ipilimumab (20) 20
metastatic melanoma (20) 20
adult (19) 19
dermatology (19) 19
melanoma - drug therapy (17) 17
pembrolizumab (15) 15
animals (14) 14
nivolumab (14) 14
skin (14) 14
aged, 80 and over (13) 13
care and treatment (13) 13
metastasis (13) 13
skin cancer (13) 13
immunology (12) 12
patients (12) 12
therapy (12) 12
skin neoplasms - drug therapy (11) 11
analysis (10) 10
antibodies, monoclonal - therapeutic use (10) 10
medicine, research & experimental (10) 10
melanoma - pathology (10) 10
complications and side effects (9) 9
immune checkpoint (9) 9
melanoma - therapy (9) 9
mice (9) 9
antibodies, monoclonal - adverse effects (8) 8
antineoplastic agents - therapeutic use (8) 8
metastases (8) 8
retrospective studies (8) 8
survival (8) 8
treatment outcome (8) 8
antineoplastic agents - adverse effects (7) 7
cell lung-cancer (7) 7
cutaneous melanoma (7) 7
diagnosis (7) 7
interleukin-12 - genetics (7) 7
malignant-melanoma (7) 7
medical prognosis (7) 7
melanoma - genetics (7) 7
myocarditis (7) 7
programmed cell death 1 receptor - antagonists & inhibitors (7) 7
research (7) 7
risk factors (7) 7
young adult (7) 7
antibodies (6) 6
biomarker (6) 6
cell death (6) 6
hematology, oncology and palliative medicine (6) 6
immunotherapy - methods (6) 6
lymphocytes (6) 6
medizinische fakultät (6) 6
melanoma - secondary (6) 6
prognosis (6) 6
safety (6) 6
skin neoplasms - pathology (6) 6
survival analysis (6) 6
tumors (6) 6
usage (6) 6
abridged index medicus (5) 5
advanced melanoma (5) 5
anti-pd-1 (5) 5
antibodies, monoclonal - administration & dosage (5) 5
cardiac & cardiovascular systems (5) 5
cytotoxicity (5) 5
inhibitors (5) 5
internal medicine (5) 5
medicine (5) 5
melanoma - metabolism (5) 5
melanoma - mortality (5) 5
mice, inbred c57bl (5) 5
multidisciplinary sciences (5) 5
mutation (5) 5
regression analysis (5) 5
research article (5) 5
antigens (4) 4
antineoplastic agents (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
apoptosis (4) 4
biomarkers (4) 4
blockade (4) 4
braf (4) 4
cancer therapies (4) 4
cell biology (4) 4
chemotherapy (4) 4
ctla-4 antigen - antagonists & inhibitors (4) 4
ctla-4 antigen - immunology (4) 4
expression (4) 4
health aspects (4) 4
health risks (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, pp. e53745 - e53745
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces... 
REGRESSION | TRIAL | INDUCED SARCOIDOSIS | CTLA-4 BLOCKADE | AUTOIMMUNITY | SAFETY | MULTIDISCIPLINARY SCIENCES | MONOCLONAL-ANTIBODY | PATIENT | HYPOPHYSITIS | CANCER | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Neoplasm Metastasis | Liver - drug effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Endocrine System - drug effects | Adult | Female | Retrospective Studies | Antibodies, Monoclonal - immunology | Kidney - drug effects | Antineoplastic Agents - immunology | Pancreas - drug effects | Gastrointestinal Tract - drug effects | Melanoma - pathology | CTLA-4 Antigen - immunology | Nervous System - drug effects | Melanoma - drug therapy | Respiratory System - drug effects | Aged | Skin - drug effects | Antimitotic agents | Antigens | Care and treatment | Algorithms | Lymphocytes | Melanoma | Skin | Metastasis | Antineoplastic agents | Skin cancer | Cancer | Aseptic meningitis | Guillain-Barre syndrome | Exanthema | Central nervous system | Blocking antibodies | Cytotoxicity | Oncology | Lymphocytes T | Metastases | CTLA-4 protein | Intestine | Gastroenterology | Meningitis | Internal medicine | Hematology | Sarcoidosis | Dermatology | Management | Regression analysis | Patients | Eosinophilia | Morbidity | Inflammatory bowel disease | Pathology | Side effects | Hospitals | Perforations | Medical prognosis | Antitumor activity | Autoimmune diseases | Endocrinology | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 210 - 225
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2018, Volume 71, Issue 16, pp. 1755 - 1764
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 190 - 209
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2018, Volume 71, Issue 11, pp. A699 - A699
Major adverse cardiac events (MACE) were defined as a composite of cardiovascular death, cardiogenic shock, cardiac arrest and complete heart block. Conclusion... 
CARDIAC & CARDIOVASCULAR SYSTEMS | Myocarditis | Heart diseases | Immune checkpoint
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 02/2019, Volume 7, Issue 1, pp. 53 - 53
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 40, pp. 67439 - 67456
Immunotherapy for metastatic melanoma offers great promise but, to date, only a subset of patients have responded. There is an urgent need to identify ways of... 
Immune suppression | PEBP1 | Dendritic cell vaccination | Immunotherapy | Melanoma
Journal Article
Cancer, ISSN 0008-543X, 10/2000, Volume 89, Issue 8, pp. 1835 - 1844
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2014, Volume 127, Issue 7, pp. 598 - 600
Journal Article
Journal of Molecular Medicine, ISSN 0946-2716, 2/2001, Volume 78, Issue 12, pp. 692 - 702
Preclinical studies investigating new therapeutic principles against melanoma are presently being carried out in mouse models; however, these are not optimal.... 
Human Genetics | Internal Medicine | Molecular Medicine | Biomedicine | Large animal Melanoma model Plasmid DNA treatment Species specificity Cytokine | Plasmid DNA treatment | Species specificity | Large animal | Melanoma model | Cytokine | cytokine | MEDICINE, RESEARCH & EXPERIMENTAL | NUDE-MICE | species specificity | VACCINE | LYMPHOCYTE MATURATION FACTOR | melanoma model | NAKED PLASMID DNA | plasmid DNA treatment | LIPOSOME COMPLEXES | THERAPY | IMMUNE-RESPONSES | IN-VIVO | GENETICS & HEREDITY | INTRAMUSCULAR GENE-TRANSFER | large animal | ANTITUMOR IMMUNITY | Immunohistochemistry | Genetic Therapy | Interleukin-12 - genetics | Horses - genetics | Humans | Male | RNA, Messenger - metabolism | Neoplasm Metastasis - immunology | Melanoma - genetics | Cell Division | Immunotherapy | Plasmids - genetics | Aging | Female | Interleukin-12 - therapeutic use | Interferon-gamma - genetics | Tumor Cells, Cultured | Disease Models, Animal | Interleukin-12 - adverse effects | Plasmids - adverse effects | Neoplasm Metastasis - therapy | RNA, Messenger - genetics | Treatment Outcome | Melanoma - pathology | Neoplasm Metastasis - genetics | Animals | Melanoma - immunology | Neoplasm Metastasis - pathology | Interleukin-12 - immunology | Melanoma - therapy | Plasmids - administration & dosage | Cancer regression | Usage | Animal models in research | Interleukin-12 | Melanoma | Physiological aspects | Research | Index Medicus
Journal Article
Tropical Doctor, ISSN 0049-4755, 07/2005, Volume 35, Issue 3, pp. 161 - 164
A range of AIDS prevention programmes suggested that cooperation between traditional healers and the biomedical primary health-care system would benefit... 
AFRICA | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | HEALTH | TROPICAL MEDICINE | Medicine | Medicine, African Traditional | Attitude of Health Personnel | Interdisciplinary Communication | Cameroon | Humans | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 75, pp. 47 - 55
Abstract Background The anti-programmed cell death-1 (PD-1) inhibitors pembrolizumab and nivolumab alone or in combination with ipilimumab have shown improved... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab |